Viking Therapeutics: The Biotech Rocket Primed for Liftoff in 2025?

Wall Street’s hunting for the next Moderna—and Viking Therapeutics might be it. This small-cap biotech’s pipeline is bubbling with treatments that could disrupt obesity, liver disease, and more. Here’s why traders are whispering ‘buy’.

The Obesity Play You Can’t Ignore

With GLP-1 drugs printing billions for Novo Nordisk and Eli Lilly, Viking’s weight-loss candidate VK2735 isn’t just chasing the trend—it’s gunning for best-in-class efficacy. Early data suggests fewer side effects than Ozempic. If Phase 2 delivers, this stock could eat Big Pharma’s lunch.

Liver Disease: A Silent Catalyst

NASH (non-alcoholic steatohepatitis) affects 12% of US adults—and Viking’s VK2809 is one of few drugs targeting it. Positive Phase 2b results sent shares up 150% overnight last year. Now, Phase 3 could turn this into a blockbuster.

Cash Burn vs. Moon Potential

Yes, Viking’s still burning cash ($120M runway as of Q2). But with short interest at 18% and institutions loading up, this is either a squeeze setup or a tragic biotech flameout. Your move—just don’t cry when the FDA decides your portfolio’s fate.